Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosamax Once-Weekly Generics Could Launch In 2008 Following Court Ruling

This article was originally published in The Pink Sheet Daily

Executive Summary

Appeals court overturns a Wilmington, Del. federal judge’s ruling and finds that a Merck patent covering once-weekly alendronate dosing is invalid. The patent was originally slated to expire in 2019, and the court decision means generic versions could enter the market 11 years earlier than expected.
Advertisement

Related Content

Merck's Fosamax Plus D To Be Priced On Par With Predecessor
Merck's Fosamax Plus D To Be Priced On Par With Predecessor

Topics

Advertisement
UsernamePublicRestriction

Register

PS060980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel